The biopharmaceutical company's shares tumbled after it announced it needs to lower the dosage of its experimental hepatitis C drug.
Link to Article
Forbes.com
|
|
||||||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Safety Concerns Slam Human Genome
by
Alex Hsieh on behalf of Professor Henry Wang
on Wed 30 Jan 2008 11:07 PM EST | Permanent Link
| Cosmos
No comments found.
|
Search
Links
|
||||||